ArticleJournal of neuro-oncology2026
Perioperative risk stratification after resection of brain metastases: internal development and validation of the dominant lesion surgery score in a 20-year single-center cohort.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine whether intracranial lesion count remains associated with survival after resection of brain metastases and to develop an internally validated perioperative risk-stratification model for early mortality in a surgically treated cohort.
methodsWe conducted a retrospective single-center cohort study of adults who underwent surgical resection for histologically confirmed brain metastases between 2002 and 2024. Overall survival was analyzed using Kaplan–Meier methods and multivariable Cox regression. The Dominant Lesion Surgery Score (DLSS) was derived from variables available during the perioperative period that were associated with early mortality and was evaluated for 6- and 12-month mortality using receiver operating characteristic analysis. Internal validation was performed with bootstrap resampling, and model performance was further assessed using calibration and decision-curve analysis.
resultsAmong 189 surgically treated patients, lesion count was not the strongest variable associated with survival after multivariable adjustment, whereas extent of resection and histology-defined tumor subtype showed stronger associations within this selected cohort. DLSS demonstrated moderate discrimination for 6- and 12-month mortality, with stable optimism-corrected performance after bootstrap validation. Calibration analysis showed acceptable agreement between predicted and observed mortality. Decision-curve analysis suggested potential net benefit across clinically relevant threshold probabilities. A DLSS cutoff of ≥ 2 identified a subgroup with higher 12-month mortality.
conclusionAmong surgically treated patients with brain metastases, lesion count alone may be insufficient to characterize postoperative risk. DLSS should be regarded as an exploratory internally derived model for perioperative risk stratification rather than a standalone tool for treatment selection, and external validation is required before broader clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.